Arbutus Biopharma Corp. (ABUS) on GreekSoup https://greeksoup.ai/stocks/us/abus/ Every dated entry in the public record on Arbutus Biopharma Corp.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Fri, 30 Oct 2026 00:00:00 +0000 Arbutus Biopharma Corp.: Schedule 13G/A filed by BlackRock, Inc., 7.2% of the classhttps://greeksoup.ai/stocks/us/abus/holders/us:ABUS:schedule-13:2026-10-27:c432632b25Tue, 27 Oct 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp. filed 8-K: other eventshttps://greeksoup.ai/stocks/us/abus/filings/us:ABUS:filing:2026-10-22:9238de78d8Thu, 22 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp.: short interest 24,566,591 shares at the 15 October 2026 settlement, 4.34 days to coverhttps://greeksoup.ai/stocks/us/abus/short-interest/us:ABUS:short-interest:2026-10-15:5195ee1a05Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp.: Schedule 13G/A filed by Morgan Stanley, 12.2% of the classhttps://greeksoup.ai/stocks/us/abus/holders/us:ABUS:schedule-13:2026-10-07:d5306a4107Wed, 07 Oct 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp.: Schedule 13D/A filed by Roivant Sciences Ltd., 19.5% of the classhttps://greeksoup.ai/stocks/us/abus/holders/us:ABUS:schedule-13:2026-10-05:ec7d6be1d4Mon, 05 Oct 2026 00:00:00 +0000Schedule 13D/13GItem 4 is hereby amended by adding the following to the end thereof: On August 24, 2026, the Issuer commenced a modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its Common Shares at prices between US$5.00 and US$5.75 per Common Share (the "Offer"), which included the option for shareholders to make a proportionate tender. Roivant made a proportionate tender of its Common Shares in the Offer in order to maintain its proportionate ownership of the Common Shares following completion of the Offer. The Offer expired at 5:00 p.m., New York City time,

Schedule 13D/13G. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp.: short interest 34,053,358 shares at the 30 September 2026 settlement, 3.53 days to coverhttps://greeksoup.ai/stocks/us/abus/short-interest/us:ABUS:short-interest:2026-09-30:1835d699a2Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp.: short interest 18,484,910 shares at the 15 September 2026 settlement, 5.01 days to coverhttps://greeksoup.ai/stocks/us/abus/short-interest/us:ABUS:short-interest:2026-09-15:8a4a4d72d6Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp.: Schedule 13G filed by Whitefort Capital Master Fund, LP, 8.0% of the classhttps://greeksoup.ai/stocks/us/abus/holders/us:ABUS:schedule-13:2026-09-04:2878a692eaFri, 04 Sep 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp.: short interest 18,916,119 shares at the 31 August 2026 settlement, 3.08 days to coverhttps://greeksoup.ai/stocks/us/abus/short-interest/us:ABUS:short-interest:2026-08-31:d062435b85Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp. filed 8-K: other eventshttps://greeksoup.ai/stocks/us/abus/filings/us:ABUS:filing:2026-08-21:3873e8f994Fri, 21 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp.: short interest 18,456,085 shares at the 14 August 2026 settlement, 15.10 days to coverhttps://greeksoup.ai/stocks/us/abus/short-interest/us:ABUS:short-interest:2026-08-14:1cbee60611Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp. Q2 FY2026 results: revenue $1 million, net income -$5 millionhttps://greeksoup.ai/stocks/us/abus/results/fy2026-q2/us:ABUS:result:2026-08-12:e09a8a6e02Wed, 12 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/abus/filings/us:ABUS:filing:2026-08-12:9924293f49Wed, 12 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/abus/filings/us:ABUS:filing:2026-08-12:edf7b2593eWed, 12 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Arbutus Biopharma Corp.: Schedule 13G/A filed by Morgan Stanley, 8.8% of the classhttps://greeksoup.ai/stocks/us/abus/holders/us:ABUS:schedule-13:2026-08-12:1853c10399Wed, 12 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]>